Opiant Pharmaceuticals, Inc. (OTCQB: OPNT) is engaged as a specialty pharmaceutical company, which develops treatments for substance abuse, addiction, and eating disorders. Shares of the pharmaceutical company gained 12.34% during trading on Monday, August 28, 2017. Over the past month, Opiant Pharmaceuticals, Inc. has seen average daily volume of 38,437 shares. However, volume of 24,529 shares or dollar volume of $575,940, exchanged hands on Monday.
Shares of Opiant Pharmaceuticals, Inc. rallied today, after the company announced it will be uplisting to the Nasdaq Capital Market. The company will continue to trade under the same symbol and will commence Nasdaq trading on August 29, 2017. Here is the full press release detailing of the uplisting:
Opiant Pharmaceuticals, Inc. Press Release:
SANTA MONICA, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that its shares of common stock were approved for listing on the Nasdaq Capital Market (“Nasdaq”). Trading on Nasdaq under the symbol “OPNT” is expected to commence on August 29, 2017.
“Our listing on Nasdaq represents a major corporate milestone for Opiant as we continue to progress into a leading player in the treatment of addictions,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “We believe that trading on Nasdaq will expand our visibility, broaden and diversify our stockholder base, provide better liquidity and ultimately contribute to our ability to increase stockholder value.”
Opiant’s common stock, which has been trading on the OTCQB Marketplace (the “OTCQB”) since April 2007, will continue to trade on the OTCQB until the market closes on August 28, 2017.
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by Opiant or any other person that the objectives and plans of Opiant will be achieved in any specified time frame, if at all. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.